SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
JAV Analysis & Videos »
JAV: Bull or Bear?
FDA Calendar Extreme Trades: 30 Stocks Under $5
JAV
|
|
|
-35.26%
in
98 days
<> Below are extreme trades among 30 companies with stock prices under $5 from the BioMedReports.com FDA Calendar, which includes 292 entries as of 8/1/09. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of BioMedReports.com, the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissions to the FDA, and pending late-stage c...
|
Extreme FDA Calendar Trades: 21 Stocks Under $5
JAV
|
|
|
+18.75%
in
12 days
(closed on 08/01/09)
<> Below are extreme trades among 21 companies with stock prices under $5 from the <font> BioMedReports.com FDA Calendar </font> , which includes 264 entries as of 7/20/09. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of <font> BioMedReports.com </font> , the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submi...
|
Extreme FDA Calendar Trades: 18 Stocks Under $5
JAV
|
|
|
+31.15%
in
17 days
(closed on 07/20/09)
<> Below are extreme trades among companies with stock prices under $5 from the <font> BioMedReports.com FDA Calendar </font> , which includes 232 entries as of 7/3/09. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of <font> BioMedReports.com </font> , the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissio...
|
Javelin Pharma: Late-Stage Pipeline Targets Pain
JAV
|
|
|
+7.83%
in
94 days
(closed on 06/17/09)
Javelin Pharma (JAV) is focused on the late stage clinical development of three Phase 3 compounds while seeking partnerships for a non-dilutive source of funding. In mid-January, JAV established a partnership for Dyloject (injectable diclofenac) with Therabel Pharma to market the drug in Europe, where it is already approved for use. <> The deal is worth up to $71M (with $12M in upfront cash and $59.5M in sales/regulatory milestones) and extends Javelin's cash resources until early 2010, during which time the Compan...
|
Buyout Binge Begins for Bio-Pharma, Diagnostics
JAV
|
|
|
-20.69%
in
64 days
(closed on 03/15/09)
<> 
<>
<> With news late Friday that Roche (RHHBY) is prepared to up its bid for complete control of Genentech (DNA) to $95 from a previous offer of $89 per share and a $41M ($1.50 per share) all-stock takeover offer by Sequenom (SQNM) for EXACT Sciences (EXAS); 2009 is off to a strong start for M&A activity in the bio-pharma and diagnostic space.
Larger and well funded bio-pharma and diagnostic companies are opportunistically looking to expand their product offerings, pipeline prospects, patent portfolios, ...
|
Nine for '09 Stock Picks Start Strong
JAV
|
|
|
-3.33%
in
2 days
(closed on 01/10/09)
<> 
The nine stock picks I posted in mid-December are off to a strong start in the new year, with seven of the stocks registering gains and a 14.5% gain for the group as an equal-weight average versus a 1.1% gain for the S&P 500 SPDR ETF (SPY). Click on any of the links below for my most recent articles on each company.
The four smallest, defensive healthcare stock picks are leading the group with an average gain of 30.6% thanks to an 87.3% gain for Javelin Pharma (JAV) and a 42.9% gain for Caraco Pharma (CPD) while...
|
FDA Calendar: Near-Term Movers
JAV
|
|
|
-42.86%
in
56 days
(closed on 12/05/08)
<> 
Some likely near-term movers on the FDA's decision date calendar for 70 different items (click to enlarge, left) include Cypress Bioscience ( CYPB ) + partner Forest Labs ( FRX ) with a pending decision on milnacipran in the treatment of fibromyalgia slated for the end of October in addition to results from a Phase 3 trial for the drug some time before year end.
Also, Discovery Labs ( DSCO ) is not listed on the calendar, but expects to file a complete response to a May 1st FDA approvab...
|
Small Pharma Large Risk Large Profit Potential
JAV
|
|
|
-81.78%
in
958 days
I have been following this stock for a couple months now. I am already about 30% up on it but I feel it has a huge upside potential. This company focuses on taking old drugs and making them better. One very interesting drug they are working on is Morphine which would be administered as a nasal spray. This would be perfect for use on the battlefield! They have several other drugs comming out soon including one which will out in Europe soon. I say buy and hold this baby for a while!
|
|
By
Q
(-21.27% risk: aggressive)
03/24/07
|
Comment
|
People Bullish on JAV
People Bearish on JAV
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
Be the first to start a discussion and earn 2 points.
More Resources
|
About Javelin Pharmaceuticals Inc
- Answers.com
